News
OTCA22 – Final Assessment Report and related documents now available
The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Point-of-care Tests (POCT): D-Dimer and Troponin’ are now available for access. Troponin
November 2019 Implementation Report – Now Available
EUnetHTA is pleased to announce the new Implementation Report with Appendices are now available for access. The report covers the updated use and uptake on
PTJA06 – “Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)” final project plan now available.
The final project plan of the assessment on polatuzumab is now available. The final assessment report will be published on 13th February, 2020. Please access
OTCA17 – Final Assessment Report and related documents now available
The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in
PTJA08 – “Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity” project plan now available.
The Final Project Plan of the assessment on siponimod is now available. The final assessment report will be published on 13th February, 2020. Please access
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’,
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’,
OTCA18 Final Assessment Report is now available.
The final assessment report and related documents concerning OTCA18, ‘regional hyperthermia for high-risk soft tissue sarcoma treatment’, are now available. The assessed technology is regional
Open Call for Patient Input for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum (NMOSD) disorders.
Patient group input requested for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum disorders. EUnetHTA deems patient involvement very important in
PTJA13 – Publication of Project Plan.
PTJA13 – Satralizumab is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in
